Ixekizumab improves sleep and work productivity in patients with non-radiographic axial spondyloarthritis: results from the COAST-X trial at 52 weeks

BACKGROUND: Patients with non-radiographic axial spondyloarthritis experience negative impacts on sleep, work productivity, and activity impairment. Ixekizumab, a monoclonal antibody selectively targeting interleukin-17A, has shown efficacy in treating the signs and symptoms of non-radiographic axia...

Descripción completa

Detalles Bibliográficos
Autores principales: Deodhar, Atul, Mease, Philip, Marzo-Ortega, Helena, Hunter, Theresa, Sandoval, David, Kronbergs, Andris, Lauzon, Steven, Leung, Ann, Navarro-Compán, Victoria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464085/
https://www.ncbi.nlm.nih.gov/pubmed/34560906
http://dx.doi.org/10.1186/s41927-021-00218-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464085/
https://www.ncbi.nlm.nih.gov/pubmed/34560906
http://dx.doi.org/10.1186/s41927-021-00218-y

Ejemplares similares